I am a Healthcare Professional outside the US and UK

I am a Healthcare Professional outside the US and UK

Click here for international medical scientific information about Oncology for Healthcare Professionals.

I am a Healthcare Professional outside the US and UK Read more
I am not a Healthcare Professional and I am outside the US and the UK

I am not a Healthcare Professional and I am outside the US and the UK

Click here for general international information for patients, caregivers and the general public.

I am not a Healthcare Professional and I am outside the US and the UK Read more
Country-specific medical scientific information

Country-specific medical scientific information

Country-specific medical scientific information for Healthcare Professionals.

This site uses cookies to improve your browsing experience. By using this site, you agree to their use. Cookie Information

InOncology.com

ASCO, CHICAGO, IL, USA, 31 May-4 JUNE 2019

A phase Ia/Ib, open label, multicenter, dose-escalation study of BI 907828 (MDM2-p53 antagonist) in adult patients with advanced or metastatic solid tumors.​

Curtis Chong, Todd Michael Bauer, Scott Andrew Laurie, Manish R. Patel, Noboru Yamamoto, Teffany Davenport, Junxian Geng, Neil Gibson, Markus P. Vallaster, Patricia LoRusso

Related Materials

Learn more about the science behind this poster in the videos, papers and other materials below.

MDM2-P53 ANTAGONIST

inoncology.com

MDM2-P53 ANTAGONIST

Related information

MDM2-p53 antagonist

Find out more about BI’s investigational MDM2-p53 antagonist, which is currently in clinical trials for the treatment of solid tumours

ASCO 2019

Find information on Boehringer Ingelheim’s activities at the ASCO 2019
Back to top

FOR HEALTHCARE PROFESSIONALS ONLY.

 

image